NIPT (safeT21, Panorama, Harmony, NIFTY)

Non-invasive Prenatal Screening or Testing. safeT21, T21 Express, NIFTY PRO, Panorama, Harmony, Faest. Booking telephone: 23682333. We are panel list clinic ... FeminaHealthcare NIPT(safeT21,Panorama,Harmony,NIFTY)   四維超聲波產前診斷中心FeminaHealthcare4DUltrasound,PrenatalDiagnosis&TreatmentCentre尖沙咀堪富利士道8號格蘭中心704-706 室(尖沙咀港鐵站A2出口)Suite704-706,GrandCentre,8,HumphreyAvenue,TsimShaTsui(TSTMTRA2Exit)23682333 Non-invasivePrenatalScreeningorTesting safeT21,T21Express,NIFTYPRO,Panorama,Harmony,Faest Bookingtelephone:23682333 WearepanellistclinicfortheAmericanConsulate,AustralianConsulate&TeachersUnion. Westrivetoensureyouhaveahealthybaby. Wecare,weprovidevariousrangeofaccurateNIPTtosuityourneed. FeminaHealthcareisestablishedin2008.Thecompanyhasservedmorethan100,000womensinceestablishment.Thevisionofthecompanyistoprovidegreatqualityhealthcareproductsandservices atreasonablepricetowomen.Thisvisionwillenablemanymorewomentoaffordgreatqualityhealthcareproductsandservices.婦健醫療中心成立於2008年。

自成立以來，該公司已為100,000多名婦女提供服務。

公司的願景是以合理的價格為女性提供優質的保健產品和服務。

這一願景將使更多婦女能夠負擔得起高質量的保健產品和服務。

Thereisnohiddencost(allinclusive,doctorfee,scan,bloodtestandlaboratoryfee),weDONOTchargeextra! NEWService:7weeksNIPT(earliestscreening);+screeningforpre-eclampsia(+$1000);SinglebloodtubeforNIPTand100genecarrierscreening NIFTYPRO$4400,NIFTYPROPlus $4800/4400andsafeT21,T21Express $4900/$6500(optionofpackagewith20weeksscan). Moreinformation: NIFTYPRO & NIFTYPROPlus; safeT21Express safeT21express,NIFTYPROPlus,Panorama,G-NIPT,FAEST,Harmony,Verifi(PreneticV)(From$2900onward!) G-NIPT,GCPharma,oneofSouthKorealargestBioPharmacologycompany FurtherdiscountisavailableonMonday,FridayandSaturday.Wecanalsoprovidenuchaltranslucency(NT)screeningtogetherwithNIPT,packagewithmid-trimesterscan. FeminaoffersmanychoicesofNIPT,haslowcostvalueaddedbrand,sellallmajorinternationalbrands,noextracostifinterchangebetweenbrand,andpriceinclusiveofultrasoundanddoctorconsultation.   Femina offersmanydifferentNIPTpricefrom$2900andabove.Only$2900canguarantee thatyouwillnothaveDownsyndromebaby.  TheaccuracyfordetectingDownsyndromeandcommonchromosomeabnormalitiesarethesameforallbrands(extensiveresearchdone). NuchalTranslucencyassessmentisessentialinfetalscreening. IncaseofoneNIPTcannotissueresult,youcanchangetoanotherbrandwithnoextracharge. RISKofDownsyndrome:20yearsold1in1000;30yearsold2in1000;40yearsold10in1000. Riskofcommonmicrodeletion1in2000orless.  RiskofgeneticdisordersnotdetectedbyNIPT 2-50in1000 VistaraandgenesafecandetectdeNovomutations,occursin2in1000abnormalbabies(from$8000). NIPT(safeT21&NIFTY)canscreenforDownsyndrome,geneticdisordersneedtodoothertests(carrierscreening,Vistaraetc). Verifi,Faest,Harmony,PanoramaallhasCollegeofAmericanPathology(CAP)certifiedLaboratories. WearethefewclinicsinHongKongofferwiderangeofhighqualityoverseaNIPTswithCAPcertifications NIFTY&safeT21expressareperformedinHongKongprivatelaboratories(notUniversity,asmostlymistaken). NIFTYPRO$4400.ALLNEWNIFTYPRO+,$4800/4400checkallchromosomes FurtherdiscountisavailableonMonday,FridayandSaturday.Wecanalsoprovidenuchaltranslucency(NT)screeningtogetherwithNIPT,packagewithmid-trimesterscan. WeofferFragileX,X-linkeddisordersandautosomalrecessivescreening. NEW:RhesusDNIPT(UKNICEguideline),avoidunnecessaryanti-DandMadCowdisease.40%ofmotherscanavoidinjection$4900. ALLbrandshavesameaccuracyforDownsyndrome.   Panoramafrom$3900/4500;Extended$4900/5500(price$6000/$8000) Faest$3000/3500(KoreanlargestBio-Technologycompany$5000)   Additionaloptions:doctorperformingscan,nuchaltranslucencymeasurement,antenatalbloodtest,carriertest,singlegenemutation 1.DoIneedNIPT?NIPTismoreaccurateandhaslessfalseresults. NIPTdetects>99%ofDownsyndrome,comparedwithOSCAR85%. 2.HowtochoosethebestNIPTforme? a)ForDownSyndrome: IfonlyforDownsyndrome,Faest,Harmony,Panoramawillbesufficient.Cheaperbutasaccuratethanmorecomplexpanels.MostO&Gcolleges(AMCOG,RCOG&RANZCOG,SMFM)recommendscreeningforDownsyndromeandnotmicrodeletionsyndromes. ALLBRANDShavethesameaccuracyfordetectingDownsyndrome(Allbrandsdetectionrate,accuracy>99%). Cheapestbrandisnotdifferentfrommostexpensiveone.LikePradaandcheaphandbagcanalsohelpyoutocarryyourpersonalbelongings. https://www.smfm.org/publications/193-cell-free-dna-screeninghttps://obgyn.onlinelibrary.wiley.com/doi/10.1002/pd.5216https://s3.amazonaws.com/cdn.smfm.org/publications/224/download-491f0e6962960848d2097447ab57a024.pdf b)Forcommonmicrodeletionssyndrome(Notcommon,lessthan1in2000): Mostcommonmicrodeletionis22q11(DiGeorgesyndrome,1in2000to4000,othersareveryrare) StandardsafeT21,Panorama,orVerifi. safeT21,Harmony&Verifidetect75%ofcommonmicrodeletionsyndromeandPanoramadetects>90%. https://www.sciencedirect.com/science/article/pii/S0002937814023746 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825123/ https://www.sciencedirect.com/science/article/pii/S1028455918302808 https://www.karger.com/Article/Fulltext/484317 Commonmicrodeletionsyndromesoccur1in2000babies. 3.Ifyouwantmostcomprehensive safeT21Advancepanel,NIFTYPRO,GenesafeorVerifi-Extend. safeT21advancepanelscreensformostconditions. BEWARE:Allthesetestsarenotvalidates,thuslikelytohavehighfalsenegativeandfalsepositiveresults(wrongresults). Overall1in100babiesmayhavenumbercopyvariants,NIPTcanscreenoutabout20=30%.   Comparisonofitems:Genesafecomplete>AdvancedsafeT21>NIFTYPRO>Verifi 4.Accuracyofsexdeterminationdependsonpanel Harmony,Faest,safeT21,Panorama(>99.5%);Verifi&NIFTY(>98%).   FACTSaboutNIPT(s): Not100%accurate. ForDownsyndrome,allbrandscandetect>99%ofDownsyndrome ForTrisomy13&18(Patau&Edwardsyndromes),differentbrandshavedifferentaccuracy. NIPTtestsDNAfromchorionicvillus,andincountingmethod,alsotestsmothers’DNA. Morecomplexpanelwillresultinmorefalsepositive,asitpicksupabnormalDNAfromplacentaandmothers(upto5/1000). Abnormalresultneedstobeconfirmedbyinvasiveprenatalprocedure(i.e.amniocentesis). NuchalTranslucency(NT)shouldbeassessed,asitcandetectotherfetalabnormalities. Fetus/babywithNT>3.5mm,shouldhaveCVSoramniocentesis,riskofmicrodeletionisincreased.EvenadvancesafeT21canonlydetectlessthan30%ofmicrodeletionsyndromes. Generalinformationofchromosomeabnormality: 1.RiskofDownsyndromeandcommonaneuploidydependonthemotherage. A20yearsoldladyhas1in1000chanceofhavingDownsyndromebaby.Thisincreasesto1in300at30yearsoldand1in100at40yearsold. 2.Riskofmicrodeletiondoesnotchangewithpatientage.Overall1in100,butonlylessthan30%canbedetectedbyNIPT. Mostcommonmicrodeletionis22q11(1in2000-4000cases). 3.Riskofsexchromosomeabnormalityisaround2-5in1000cases. NIPTformicrodeletionsyndromes MajorityofmicrodeletionandduplicationsyndromescannotbedetectedbyNIPT.Evenmostadvancedpanel(NIFTYPROorsafeT21)canonlydetectlessthan25%ofcopynumbervariants.Ifthereareindications,prenatalinvasivetestingshouldbeperformed. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351230/table/table1-0022155412440001/ AmericanCollegeofObstetricians&Gynecologists(ACOG),AmericanMedicalGeneticSociety,andSocietyofMaternalandFetalMedicineadviceAGAINSTscreeningformicrodeletionwithNIPT.UsingNIPTtoscreenformicrodeletionwillincreaseunnecessaryinvasivetestingwithverylowpositivepredictivevalue.Italsoprovidesfalsereassurance,aslessthan25%ofcopynumbervariantscanbedetected. ACOG:“Routinecell-freeDNAscreeningformicrodeletionsyndromesshouldnotbeperformed.” https://www.contemporaryobgyn.net/obstetrics/acog-guidelines-glance-screening-fetal-aneuploidy https://journals.lww.com/greenjournal/Fulltext/2015/09000/Committee_Opinion_No__640__Cell_Free_Dna_Screening.51.aspx 4.Sexdetermination(gender) Harmony,Faest,safeT21,Panorama(>99.5%);Verifi&NIFTY(>98%).   COMPANYINFORMATION safeT21,Xcelom(subsidiaryof BerryGenomics,Beijing,China). NIFTYPRO,BGI,HongKong(subsidiaryof BGI Shenzhen,China). Panorama,Natera,California,UnitedStatesofAmerica. Harmony,Roche,UnitedStatesofAmerica. Verifi,Illumina, UnitedStatesofAmerica. Faest,Macrogen,SouthKorea(worldno6largestBiotechnologycompany) Genesafe, Eurofin,Europe(oneofthelargestBiotechnologycompanyinEurope;UK,NetherlandandItaly). KeymessagesandQ&Adocumentforwomen WhatarethekeymessagesforwomenfromthisRoyalCollegeofObstetrician&Gynecologists(RCOG)ScientificImpactPaper? Non-invasivePrenatalTesting(NIPT)usesanordinarymaternalbloodsampleandcarriesnorisktothemotherorherbaby. NIPTusesfetalDNAfromtheplacentaandismuchmoreaccuratethanpreviousscreeningtests.Itdoesnothavetherisksofthecurrentinvasivetests,whichcarryasmallbutsignificantriskofmiscarriageandwillbeneededmuchlessoften. Itisalreadybeingusedforsomeconditions,however,itisbecomingaprimaryscreeningmethodforchromosomalabnormalities,suchasDownsyndrome,inpregnancy. Thehighdegreeofaccuracy,however,meansthatpregnantwomenmaybeinformedoffindingsofuncertainsignificance,suchasplacentalmosaicism,whenthereisadiscrepancybetweenthechromosomalmakeupofthecellsintheplacentaandthecellsinthebaby,whichcanresultinahealthypregnancy,however,insomepregnanciesitcanleadtocomplications. Excellentcommunicationbetweenwomenandhealthprofessionalsisthereforeessentialtounderstandingtheimplicationsofthetestresultsandfamiliesneedpre-testinformationandsupportforinformeddecisionmaking. Q&A   1.Whatisthedifferencebetweeninvasiveandnon-invasiveprenataltesting? Invasiveprenataltestingsuchasamniocentesisinvolvesneedlesbeinginsertedintotheuterustodetectchromosomalabnormalities.Thismethodcarriesasmallbutsignificantriskofmiscarriage. Non-invasiveprenataltestingisanewtechniquethatusesDNAfromthebabypresentinapregnantwoman’sbloodfromearlypregnancyandisamuchmoreaccurateformofscreeningforanumberoffetaldisorders,suchasDownsyndrome.Itisobtainedviaanordinarybloodtestfromthemother. 2.Whatisnon-invasiveprenataltestingcurrentlyusedfor? Obstetricianscurrentlyusenon-invasiveprenataltestingtoguidewomenwhosebabyisatriskofhaemolyticdiseaseofthefetusandnewborn(HDFN),aconditionwhereantibodiesdevelopinapregnantwoman’sbloodandsubsequentlydestroythebloodcellsofthebabysheiscarrying. Itisalsousedforfetalsexdeterminationinpregnanciesathighsex-linkedgeneticrisk,suchasDuchennemusculardystrophy,aninheritedconditionwhichaffectsthemuscles,causingmuscleweakness. InsomepartsoftheworldandintheUKintheprivatesector,NIPTisnowavailabletodetectDownsyndromeandotherchromosomalabnormalities. 3.Whattypeofconditionswillnon-invasiveprenataltestingscreenfor? Non-invasiveprenataltestingisabletodetectthebaby’sbloodgroup,sex-linkeddiseases,andchromosomalabnormalities.Thereisthepotentialforothergeneticconditionstobedeterminedinthisway.   4.Howaccurateisnon-invasiveprenataltesting? Non-invasiveprenataltestingishighlyaccurate.However,possiblesourcesoferrorincludethetestbeingundertakentooearly(before10weeks),orduetomaternalobesity. Furthermore,thetestresultdoesnotpredicttheseverityoftheabnormalityandfurthertestingmaybenecessary. 5.Arethereanyriskstothemotherandbabyifnon-invasiveprenataltestingisconducted? Non-invasiveprenataltestingcarriesnorisktomotherorbaby.Thesamplerequiredisanordinarybloodtesttakenfromthemother. 6.Atwhatstageofthepregnancywouldnon-invasiveprenataltestingbeconducted? Non-invasiveprenataltestingshouldbeconductedafter10weeksofpregnancy.Ifthetestiscarriedoutbefore10weekstheremaybeinsufficientfetalDNAcirculatinginthemother’sbloodtocarryoutthetest. 7.HowisNIPTdifferentfromthecombined/triple/quadrupletest? Althoughbothtestsinvolveasampleofmaternalblood,NIPTanalysesthecell-freeDNAinthemother’sblood,whereasthecombinedandquadrupletestanalysesthemother’shormonelevels.Withmorethan99%accuracy,NIPTismoreaccuratethanthefirsttrimestercombinedtestorsecondtrimesterquadrupletestforestimatingthechanceortheriskthatthebabyhasDownsyndrome.   ‘NIPTismoreaccuratethanthecombinedorquadrupletestforestimatingtheriskofDownsyndrome’ 8.WhatresultscanwegetfromNIPTforDownsyndrome? TherearethreepossibleresultsfromNIPTforDownsyndrome:     Positive:PredictedtobeaffectedbyDownsyndrome.Aninvasivetestshouldbeofferedtoconfirmtheresult. Negative:HighlyunlikelytobeaffectedbyDownsyndrome. Inconclusive:Inconclusiveresultshappeninupto1-2%ofcases.ThisisusuallybecausetheproportionoffetalDNApresentinthesampleisnothighenoughtogiveanaccurateresult.NIPTmayberepeatedwiththehopethatthecffDNAlevelswillhaveincreasedduetotheincreasedgestation. NIPTdetectsaround98-99%ofallbabieswithDown,EdwardsandPatausyndromes. 9.Whyaretheresultsnot100%accurate? Bothpositiveandnegativeresultsmaybeinaccurateduetothefollowingreasons:   Falsepositives Theseoccurinaround0.3%ofcases(or1in300).Possiblecausesoffalsepositiveresultsinclude:     Whenusedearlyinpregnancy,cell-freeDNAfroma‘vanishingtwin’maybepresent,astheplacentacontinuestoshedfetalDNAafterembryonicdemise.Ascanisneededtolookformultiplepregnanciesoranemptysacpriortothetest. Thecell-freefetalDNAcomesfromtheplacenta,andweknowthatsometimesthereare‘celllines’thatgrowintheplacentabutnotthebaby.Thisiscalled‘confinedplacentalmosaicism’causingafalsepositiveresult,whichreflectsanabnormalcelllinethatisonlypresentintheplacentabutnotpresentinthebaby. Veryoccasionally,becausewearetestingallthecell-freeDNAinthemother’sblood(thisincludesthemother’sandthebaby’sDNA),wemaydetectaproblemthatispresentinthemotherbutnotthebaby.   Falsenegatives NIPTdetectsmorethan98-99outof100ofallbabieswithDown,EdwardsandPatausyndromes.Possiblecausesoffalsenegativeresultsinclude:   TheproportionoffetalDNApresentinthebloodistoolow.Thismaybeduetoearlygestationortothemother’sBMIbeinghigh.Ascanisneededtoconfirmgestationpriortothetest. Thecell-freefetalDNAcomesfromtheplacenta,andweknowthatsometimesthereare‘celllines’thatgrowintheplacentabutnotthebaby.Thiscancauseafalsenegativeresultifanabnormalcelllineisonlypresentinthebabybutnotintheplacenta. Technicalissues. ‘NIPTdetectsmorethan98-99outof100babieswithDownsyndrome’   10.Whatsupportisavailable? Followingthenon-invasivetest,iftheresultshowsanabnormality,thewomanwouldbeofferedfurthertestingtore-confirmthediagnosis.Ateamofobstetriciansandmidwiveswouldprovidethenecessarycounsellingandadviceforfamilies. 11.WherecanIfindmoreinformationaboutnon-invasiveprenataltesting? TheRAPIDresearchprogrammehasaguidetonon-invasiveprenataltesting: http://www.rapid.nhs.uk/guides-to-nipd-nipt/introduction/ PublicHealthEnglandhasfurtherinformationonnon-invasiveprenataltestingforDownSyndrome: http://fetalanomaly.screening.nhs.uk/programmestatements FeminaHealthcareWebsite(willupdate) NIPTwebsite(willupdate) 12.WherecanIfindoutmoreaboutcurrentscreening? CurrentlyallpregnantwomenintheUKareofferedatestforfetalanomalies,includingDownSyndrome,aspartofTheNHSFetalAnomalyScreeningProgramme(NHSFASP). MoreinformationonthecurrentfetalanomalyscreeningprogrammecanbefoundontheNHSFASPwebsite:http://fetalanomaly.screening.nhs.uk/testsabout.                     Resources Searchfor: English 繁體中文 简体中文 Copyright2022FeminaHealthcare-GridBulletinTheme|PoweredbyNethubOnlineLimitedWebHosting